Amgen alliance 'evolution' of AstraZeneca's peer-to-peer deal model
This article was originally published in Scrip
"We like these peer-to-peer collaborations, they are a good way to work," AstraZeneca's vice president of strategic partnering and business development, Shaun Grady, told Scrip. He was discussing this week's announcement that the Anglo-Swedish pharma has signed an agreement with Amgen to jointly develop and commercialise five monoclonal antibodies from Amgen's clinical inflammation portfolio, including the Phase III-ready brodalumab (AMG827). The other four assets are in Phase I (scripintelligence.com, 3 April 2012).